Key Points for Decision Makers {#FPar1}
==============================

This is the first validated economic model to be published for C282Y homozygote haemochromatosis for the Australian setting utilising utilities and costs from a haemochromatosis cohort.From the government perspective, mean discounted lifetime direct medical costs for C282Y homozygote males were estimated to be more than 1.5 times that of females (\$A22,737 vs. \$A13,840).The model estimated mean discounted quality-adjusted life-years associated with the current screening approach were 15.654 for males and 14.390 for females.This model can be used by decision makers to identify cost-effective screening and treatment strategies for C282Y homozygote haemochromatosis.

Introduction {#Sec1}
============

*HFE*-associated hereditary haemochromatosis is the most common monogenic disorder amongst populations of northern European ancestry \[[@CR1]--[@CR3]\]. Whilst several mutations of the *HFE* gene have been identified, C282Y homozygotes account for between 80 and 90% of the burden of disease \[[@CR4], [@CR5]\]. The prevalence of this genotype has been estimated to be between 1 in 150 and 1 in 200 in populations of northern European ancestry (i.e. UK, Ireland and Scandinavian countries) \[[@CR6]--[@CR9]\]. Prevalence in populations of other ancestries is far lower, with estimates in the range of 1 in 1000 for both First Nation and African Americans \[[@CR10]\] and 1 in 1 million amongst Asian populations \[[@CR11]\].

Clinically, haemochromatosis is characterised by iron overload, with excess iron stored in the parenchymal tissues of the liver, heart and pancreas \[[@CR2], [@CR12], [@CR13]\]. Early symptoms of iron overload are non-specific, including fatigue, lethargy and arthropathy of the metacarpophalangeal joints. As iron overload progresses, liver disease, heart disease and type 2 diabetes mellitus can occur. Clinical penetrance is incomplete: a further genetic mutation is thought to play a role in this process \[[@CR14], [@CR15]\]. Whilst age of onset of iron overload varies, males typically develop overload at an earlier age as menstruation assists in reducing iron stores in females \[[@CR6]\].

Both diagnosis and treatment of haemochromatosis are straightforward. The former involves iron studies, most importantly transferrin saturation (TfS) and ferritin, with confirmatory *HFE* genotyping. Treatment involves regular therapeutic venesection. When treatment is commenced prior to organ damage and maintained, the patient will not experience any long-term health problems related to haemochromatosis and retains normal life expectancy (LE). However, as the early symptoms of haemochromatosis are non-specific, timely diagnosis is often missed until organ damage has occurred \[[@CR16], [@CR17]\]. In order to increase early diagnosis, population screening programmes have been suggested \[[@CR18]--[@CR21]\].

Screening programmes are typically resource intensive, and therefore decision makers need to be confident that such interventions are likely to be cost effective prior to their introduction. Economic modelling is a method that assists decision makers to evaluate the cost effectiveness of a given intervention \[[@CR22]\]. Long-term costs and consequences of the disorder with or without screening can be predicted by using existing clinical, epidemiological and cost data combined in a suitable model. However, to date, no health economic model based on costs and utilities from a haemochromatosis cohort has been published. To address this lack of evidence, we have developed a model to assess screening strategies for the Australian setting for people homozygous for the C282Y mutation. The aim of this paper is to describe the construction and validation of our haemochromatosis screening model and to present model predictions for LE, quality-adjusted life-years (QALYs) and total lifetime costs associated with haemochromatosis.

Methods {#Sec2}
=======

Model Structure {#Sec3}
---------------

We constructed a cost-effectiveness model using a Markov approach allowing for modelling of multiple disease states over a lifetime horizon. The cycle length was 1 year, which continued to run until the death of all simulated subjects. A lifetime horizon was selected to reflect the chronic nature of haemochromatosis. The perspective taken was that of the government. This perspective was adopted as funding decisions are based, in part, on these government costs. Both costs and effectiveness were discounted annually by 5%, in line with the Australian guidelines \[[@CR23]\]. The structure of the model is detailed in "Appendix [1](#Sec20){ref-type="sec"}". The model was constructed using TreeAge Pro Suite 2014 (TreeAge Software, Williamstown, MA, USA). Validation was conducted using TreeAge Pro and SPSS^®^ version 22.0.0.0 (IBM Corp., Armonk, NY, USA). Modelled output data were exported into SPSS^®^ allowing for calculation of correlation coefficients and fitting linear curves for goodness-of-fit analyses.

Markov states were categorised according to the European Association for the Study of the Liver's (EASL) recommendations pertaining to how research on haemochromatosis is reported (Table [1](#Tab1){ref-type="table"}) \[[@CR18]\]. The four categories represent increasing severity of haemochromatosis and iron overload. For the Markov model, an absorbing 'Death' state was also included. Figure [1](#Fig1){ref-type="fig"}a, b provide an overview of the possible transitions between these states ("Appendix [1](#Sec20){ref-type="sec"}" provides a more detailed flowchart showing the steps in the screening process). Simulated participants could move in either direction between the four categories of haemochromatosis for all disease states except Category 4, as this included irreversible organ damage, and could also move to the absorbing state of 'Death'. Clinical pathways that were incorporated into the model (screening, diagnosis and treatment) were based on current guidelines and input from an expert clinician (KCY). The model structure was designed by a health economist/clinician (AJP) and three health economists (BdG, LS, ALN).Table 1Categories of haemochromatosis \[[@CR17]\]Category 1Genetic mutation only (C282Y homozygotes, H63D heterozygotes and compound heterozygotes)Category 2Genetic mutation and elevated iron studies, either transferrin saturation or serum ironCategory 3Genetic mutation, elevated iron levels and early symptoms (e.g. arthritis, fatigue, lethargy)Category 4Genetic mutation, elevated iron levels and organ damage (e.g. liver cirrhosis, hepatocellular carcinoma, heart disease, type 2 diabetes mellitus) Fig. 1**a** Overview of model structure. **b** Transitions from haemochromatosis categories based on adherence to treatment. *HMZ* homozygote, +*ve* positive, --*ve* negative

Probabilities were calculated for each possible transition through the model, as outlined in Fig. [1](#Fig1){ref-type="fig"}. These annual probabilities were calculated based on data from an epidemiological study \[[@CR6]\] (Table [2](#Tab2){ref-type="table"}). Transition probabilities were mediated by adherence to treatment, i.e. non-adherence led to a higher probability of a participant moving to a more severe category of haemochromatosis. Transition probabilities for the 'Death' state were set at age- and sex-specific mortality rates for the Australian population \[[@CR24]\] for all states with the exception of Category 4. As Category 4 is characterised by irreversible organ damage, a higher probability of death was assumed, as discussed in Sect. [2.1.5](#Sec8){ref-type="sec"}.Table 2Key model parametersParameterBase caseRange for SADistributionSourceMalesFemalesMalesFemalesPrevalence of C282Y homozygotes^a^0.00680.00680.0044--0.00740.0044--0.0074Triangular\[[@CR6], [@CR8], [@CR9], [@CR18]\]Probabilities for categories of haemochromatosis Category 10.80.950.64--0.096^b^0.76--1.00^b^Triangular\[[@CR9], [@CR18]\] Category 20.20.050.16--0.24^b^0.04--0.06^b^Triangular Category 300 Category 400Annual transition probabilities\[[@CR9], [@CR54]\] With treatment  Category 1 to 200  Category 2 to 11--(mortality^c^)1--(mortality^c^)  Category 2 to 300  Category 3 to 20.00830.00830.0064--0.0096^b^0.0064--0.0096^b^Triangular  Category 3 to 400  Category 4 to die0.01670.01670.0134--0.0200^a^0.0134--0.0200^a^Triangular Without screening and/or treatment  Category 1 to 20.0710.05420.0568--0.0852^b^0.04336--0.0650^b^Triangular  Category 2 to 100  Category 2 to 30.06250.01670.050--0.075^b^0.0134--0.0200^b^Triangular  Category 3 to 40.00830.00830.0064--0.0096^b^0.0064--0.0096^b^Triangular  Category 4 to die0.01670.01670.0134--0.0200^b^0.0134--0.0200^b^TriangularAdherence to therapeutic venesection (3--4 times annually) Year 10.9050.724--1.000^b^Triangular\[[@CR30]\] Year 20.8370.670--1.000^b^Triangular Year 30.7690.615--0.923^b^Triangular Year 40.7010.561--0.841^b^Triangular Year 50.6330.506--0.760^b^Triangular Year 60.5650.452--0.678^b^Triangular Year 70.4970.398--0.596^b^Triangular Year 80.4290.343--0.515^b^Triangular Year 90.3610.289--0.433^b^Triangular Year 10 and thereafter0.2930.234--0.352^b^TriangularGovernment costs incurred in categories of haemochromatosis^d^ Category 1824434--1213^b^Log-normal\[[@CR34]\] Category 219491162--3018^b^Log-normal Category 336812945--4417^b^Log-normal Category 410,3938313--12,472^b^Log-normalUnit costs of screening strategy elements^d^ GP Level A16.95n/a\*Log-normal\[[@CR33], [@CR55]\] GP Level B37.05n/a\*Log-normal Iron studies27.70n/a\*Log-normal *HFE* genotype: blood31.00n/a\*Log-normal Initial medical specialist appointment72.75n/a\*Log-normalSensitivity HFE genotype0.920.920.736--1.00^b^0.736--1.00^b^TriangularGenotype \[[@CR41]\]; transferrin saturation \[[@CR42]\] First transferrin saturation0.9380.5460.750--1.00^b^0.437--0.655^b^Triangular Second transferrin saturation0.900.550.72--1.00^b^0.44--0.66^b^TriangularSpecificity *HFE* genotype0.9940.9940.795--1.00^b^0.795--1.00^b^Triangular First transferrin saturation0.9810.9810.785--1.00^b^0.785--1.00^b^Triangular Second transferrin saturation0.9960.9940.797--1.00^b^0.795--1.00^b^TriangularUptake of screening Population^a^0.050.025--0.075^e^TriangularEstimates^f^  Of these:   Cascade screening0.50Triangular   Incidental screening0.50TriangularUtilities Category 10.880.710.70--1.00^b^0.57--0.85^b^Beta\[[@CR38]\] Category 20.850.770.68--1.00^b^0.62--0.92^b^Beta Category 30.590.600.47--0.71^b^0.48--0.72^b^Beta Category 40.590.410.47--0.71^b^0.33--0.49^b^BetaAnnual discount rate Costs0.050.00--0.07\[[@CR23]\] Effectiveness0.050.00--0.07*GP* general practitioner, *HFE* the gene largely responsible for haemochromatosis, *n/a* not applicable, *SA* sensitivity analysis\* SA was carried out on total screening costs, not unit costs^a^This refers to persons of northern European ancestry^b^One-way SA values ±20% of base-case value^c^Mortality rates used were age and sex specific, and obtained from the Australian Bureau of Statistics \[[@CR24]\]^d^All costs are in 2015 Australian dollars^e^One-way SA values ±50% of base-case value^f^These estimates were based on expert opinion as no data were available

### Base-Case Populations {#Sec4}

Two base-case populations were selected for analysis: males 30 years of age and females 45 years of age, both of northern European ancestry. The rationale for this decision was based on prevalence and penetrance estimates. Northern European ancestry was chosen as the prevalence of C282Y homozygosity is far higher than reported for populations of other ancestries \[[@CR6], [@CR10]\]. Amongst males, iron overload and related complications typically occur from the age of 30 years onwards, and this has been the preferred age in other haemochromatosis models \[[@CR25]--[@CR27]\]. The second base-case population consisted of females 45 years of age, as females tend to experience iron overload following commencement of menopause \[[@CR28]\].

### Screening {#Sec5}

A single screening strategy was modelled for validation purposes, which was based on the status quo approach in Australia. Screening was assumed to occur at age 30 years for males and 45 years for females. Screening occurs either through a cascade approach, in which first-degree relatives of a homozygote are offered genotyping, and iron studies reimbursed by the Medical Benefits Scheme (MBS). Alternatively, screening occurs incidentally, consisting of a three-step process: two consecutive elevated TfS tests followed by *HFE* genotyping. In our model, when a participant tested negative to the genotype test, a referral to a specialist medical practitioner for further investigation was assumed ("Appendix [1](#Sec20){ref-type="sec"}"). Genetic counselling was assumed to take place during the medical consultations conducted before and after *HFE* genotyping. At present, this combined approach is estimated to diagnose 31% of C282Y homozygotes in Australia (L. Gurrin, Principal Investigator, HealthIron study, personal communication, 16 March 2015).

As no data were available to inform uptake of cascade and incidental screening in Australia, expert opinion and literature were relied on to inform this. The uptake rate for any screening for a population of northern European ancestry was estimated to be 5% \[[@CR29]\]. This group was then equally divided as to whether they were screened via a cascade or incidental approach.

Estimates for adherence to treatment were taken from a longitudinal study describing this over a 9-year period \[[@CR30]\]. Based on this study, patient adherence was set at 90.5% in year 1, decreasing linearly to 29.3% in year 9. For the purposes of the model, the estimate of adherence plateaued at 29.3% from year 10 onwards. Adverse events associated with treatment were not included in the model as venesection is considered a safe treatment, with adverse events typically limited to dizziness and/or syncope subsequent to treatment \[[@CR30], [@CR31]\]. In Australia, the clinician providing venesection typically provides care to the patient.

### Costs {#Sec6}

Costs were reported from the government perspective, and were limited to direct medical costs, although other costs (indirect and direct non-medical costs) can also be included in the model. The costs were screening and state (category) costs, both of which were reported in 2015 Australian dollars (\$A) (0.75 US dollars). Costs were deflated to constant prices using the price index for Government final consumption expenditure on hospitals and nursing homes for 2013/2014 \[[@CR32]\].

Direct medical costs associated with screening were sourced from the 2015 MBS \[[@CR33]\]. Specific costs related to genetic counselling were not included, as this was assumed to be provided by the medical practitioner during the consultations conducted before and after *HFE* genotyping. Costs were based on the assumption that repeat testing, related to either collection or analysis errors, was not required.

The costs associated with haemochromatosis states were sourced from our previous cost-of-illness study \[[@CR34]\]. This study estimated the costs of haemochromatosis on the basis of a national survey using a bottom-up approach. To date, these are the only published cost estimates for haemochromatosis. Costs were reported for each of the four EASL categories of haemochromatosis and are defined in Table [2](#Tab2){ref-type="table"}. These costs were used for hypothetical participants who were diagnosed and received treatment. For participants either not diagnosed or not adhering to treatment, treatment costs, i.e. therapeutic venesection, were subtracted from the total costs for each category. Further, costs for undiagnosed Category 1 patients (either not screened or a false-negative test) were set a zero. A brief description of the costing methodology is included here, but readers are directed to the original paper for a more detailed description \[[@CR34]\].

Costs included were limited to resources funded by federal or state and territory governments. Pharmaceutical costs were based on the subsidy from the 2015 Pharmaceutical Benefits Scheme (PBS) Price Schedule of 1 January 2015 \[[@CR35]\]---the difference between the dispensed price and the co-payment, if the dispensed price is greater. Unit costs for medical consultations and investigations (blood tests, liver biopsies, X-rays, etc.) were derived from the *Medicare Benefits Schedule Book* \[[@CR33]\]. The *National Hospital Cost Data Collection* cost weights for Australian Refined Diagnosis-Related Group (AR-DRG) version 6.0 × (2011--2012) were used to estimate public hospital events \[[@CR36]\]. Costs for public outpatient admissions were costed as reported by the Independent Hospital Pricing Authority \[[@CR37]\].

### Effectiveness {#Sec7}

Health state utility values (HSUVs) were used to calculate QALYs. Utility values were taken from a recently published study by our group, the only study to date that has assessed utility values directly in people with haemochromatosis \[[@CR38]\]. This study reported HSUVs amongst a sample of Australian adults with haemochromatosis, using the Assessment of Quality of Life 4D (AQOL-4D) instrument \[[@CR38]\]. Mean utilities and their distributions were calculated for each of the four EASL categories (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).

### Mortality {#Sec8}

Mortality associated with haemochromatosis was assumed to be the same as the Australian population age- and sex-adjusted rates, with the exception of Category 4. Age- and sex-adjusted mortality was sourced from Australian life tables \[[@CR24]\], which are based on demographic data collected by the Australian Government for the entire population (Table [2](#Tab2){ref-type="table"}). For Category 4, as irreversible organ damage (e.g., liver cirrhosis, heart disease) characterises this category, an elevated probability of death was assigned to this state reflecting current literature. A multiplier of 2.45 (95% confidence interval \[CI\] 2.27--2.64) was applied to the age- and sex-specific mortality rates for the Australian population, based on an estimate from an epidemiological study \[[@CR39]\].

### Bayes' Revision {#Sec9}

As with almost all diagnostic tests, the sensitivity and specificity of TfS and *HFE* genotyping as diagnostic tools for haemochromatosis are imperfect, i.e. both less than 100%. To address this, the Bayes' revision function within the TreeAge model structure was used. This function, based on Bayes' theorem \[[@CR40]\], combines prior and posterior probabilities (or, alternatively, combines a prior odds with a likelihood ratio to generate a posterior odds for a given hypothesis) as per the following formula (Eq. [1](#Equ1){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ P({\text{Hypothesis|Evidence}}) = \frac{{P ( {\text{Evidence|Hypothesis}}) \times P({\text{Hypothesis}})}}{{P({\text{Evidence}})}} $$\end{document}$$where *P*(Hypothesis) is the prior probability of the hypothesis of disease (usually taken to be the unadjusted population prevalence if we are considering a diagnostic test for a binary outcome) and *P*(Evidence) is the marginal probability of the evidence given that the hypothesis is true, usually derived from a 'sampling model' for the probability of the observed data given values of the sensitivity and specificity consistent with the hypothesis. The model incorporated four posterior probabilities in both the incidental and cascade screening sub-branches, specific to the tests ordered. The estimates of sensitivity and specificity for genotyping \[[@CR41]\] and TfS tests \[[@CR42]\] are displayed in Table [2](#Tab2){ref-type="table"}.

Sensitivity Analyses {#Sec10}
--------------------

Probabilistic decision analysis with simultaneous sampling from distributions of key input parameters was used to address uncertainty. Tornado diagrams were produced for both populations to identify parameters with the greatest individual impact on costs and effectiveness. Prevalence of C282Y homozygosity, adherence to treatment, transition probabilities, Category 4 mortality rates, utility values and costs were varied by ±20% of the values used in the base-case analysis \[[@CR43]\]. Screening uptake was varied by ±50% of the values used in the base-case analysis, reflecting the greater uncertainty given reliance on expert opinion. Discounting of both costs and effectiveness was varied between zero and 7%, from the base-case of 5%. Based on these results, one-way sensitivity analysis of all key input parameters was performed. For variables that were defined by a distribution, probabilistic sensitivity analysis was conducted to incorporate multiple parameter uncertainties simultaneously.

Model Validity {#Sec11}
--------------

Validation of the model followed the recommendations of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Task Force-7 \[[@CR44]\]. Face and internal validity were addressed; however, as no long-term data were identified that could be used to assess external validity, this was not conducted. Face validity is a subjective approach involving people with clinical expertise in the disease area, thus ensuring the model incorporates the highest level of clinical evidence. The overall structure of the model, population, screening approaches, outcomes and assumptions were reviewed and validated by a hepatologist (KCY), biostatistician (LCG) and four health economists (AJP, LS, BdG, ALN).

Internal validity involved assessments to ensure the correct mathematical calculations were implemented. This was conducted by validating equations and parameters against their sources (BdG, LS). Modelled mortality rates, LE and prevalence for C282Y homozygosity for males and females at various ages were compared with the mortality data that were used to populate the model \[[@CR24]\] and prevalence estimates \[[@CR10], [@CR42], [@CR45]\]. One-way sensitivity analyses were conducted, as previously discussed, to ensure the results changed as expected when input parameter values were varied.

Results {#Sec12}
=======

Results of Validity Assessment {#Sec13}
------------------------------

### Face Validity and Internal Validation {#Sec14}

For face validity, the model structure was found to represent all clinical aspects of haemochromatosis correctly \[[@CR7], [@CR17], [@CR46], [@CR47]\]. To assess internal validity, mortality rates and LE generated by the model were compared with the published rates used to build the model (Table [3](#Tab3){ref-type="table"}) \[[@CR24]\]. The modelled predictions for mortality rates for males (at ages 30, 40, 50, 60, 70 and 80 years) and females (at ages 45, 55, 65, 75 and 85 years) were plotted against the published rates and the goodness of fit for the linear relationship assessed (Fig. [2](#Fig2){ref-type="fig"}a). The correlation coefficient (*R* ^2^) was 1.00, indicating the model accurately reproduced the inputted mortality rates. Similarly, for the overall cohort, the model predicted LE of 30-year-old males to be 51.0 years, identical to the data reported in the Australian Bureau of Statistics' (ABS) Life Tables (51.0 years) (Table [3](#Tab3){ref-type="table"}) \[[@CR24]\]. For females aged 45 years, the model predicted LE of 40.4 years, consistent with the data from the ABS Life Tables (40.4 years). These findings were as expected, given the relatively low prevalence of C282Y homozygotes. Further, the penetrance of Category 4---the only state with elevated mortality rates---is very low, ranging between 0 and 0.01% (Fig. [4](#Fig4){ref-type="fig"}a, b). *R* ^2^ was 1.00, indicating the model accurately calculated LE (Fig. [2](#Fig2){ref-type="fig"}b). The model also predicted prevalence of C282Y homozygosity for male and female cohorts (Table [3](#Tab3){ref-type="table"}). The model predicted a prevalence rate of 0.62%, similar to the rate reported from a large prevalence study of northern Europeans (0.75%) \[[@CR42]\], and *R* ^2^ was 0.905.Table 3Internal validity from model predictionsParametersAnnual mortality rate from model predictionsAnnual mortality rate from literature \[[@CR24]\]Mortality rates for males at ages (years) 300.000790.00079 400.001340.00134 500.002910.00291 600.006780.00678 700.016900.01691 800.051260.05126Mortality rates for females at ages (years) 450.001210.00121 550.002700.00270 650.006260.00626 750.017830.01783 850.066030.06603Model predictionsData from literatureLife expectancy (years) Male aged 3051.051.0 \[[@CR24]\] Female aged 4540.440.4 \[[@CR24]\]Prevalence of C282Y homozygotes amongst persons of northern European ancestry^a^ (%) Males0.62 (0.0006)0.75 \[[@CR42]\]; 0.68 \[[@CR6]\]; 0.44 \[[@CR10]\] Females0.62 (0.0006)^a^Whilst the prevalence of C282Y homozygosity is the same for both sexes, the model was run separately for males and females. As a result, they are reported separately Fig. 2Goodness-of-fit test: (**a**) annual mortality rates for males and females---mortality rates were reported for males at ages 30, 40, 50, 60, 70 and 80 years and for females at ages 45, 55, 65, 75 and 85 years; (**b**) life expectancy for males aged 30 years and females aged 45 years

Model Predictions {#Sec15}
-----------------

Table [4](#Tab4){ref-type="table"} displays the results of the base-case Monte-Carlo simulations, calculated from age 30 years for males and 45 years for females. LE was estimated specifically for C282Y homozygotes: for 30-year-old males, LE (standard deviation) was estimated to be 49.9 years (0.04), 1.1 years less than the Australian LE for 30-year-old males (51.0 years). The projected LE for female C282Y homozygotes aged 45 years was 40.2 years (0.01), 0.3 years less than the Australian LE for females of the same age (40.4 years). The mean (95% CI) discounted QALYs associated with screening were 15.7 (7.7--23.7) for males and 14.4 (6.7--22.1) for females. Figure [3](#Fig3){ref-type="fig"}a, b illustrate the dispersion of the cost and effectiveness results in scatterplots. The model also predicted mean lifetime direct medical costs (95% CI) for male C282Y homozygotes as \$A22,737 (3670--85,793) and \$A13,840 (1335--67,377) for females.Table 4Results of base-case analysesMales (age 30 years) (SD)Females (age 45 years) (SD)LE (C282Y homozygotes)49.9 (0.04)40.2 (0.01)Population^a^C282Y homozygotesCosts (2015 \$A)Effectiveness (QALYs)Costs (2015 \$A)LE (years)Males Mean14515.65422,73749.91 Standard deviation1484.06225,1040.04 95% CI29--4987.694--23.6683670--85,793--Females Mean9114.39013,84040.15 Standard deviation1353.95522,6960.01 95% CI15--4146.660--22.1421335--67,377--Time (years) in disease statesC282Y homozygotesMales (SD)Females (SD)Category 110.42 (0.00)14.77 (0.00)Category 213.53 (0.00)19.54 (0.00)Category 323.19 (0.00)5.51 (0.00)Category 42.79 (0.04)0.41 (0.01)*\$A* Australian dollars, *CI* confidence interval, *LE* life expectancy, *QALYs* quality-adjusted life-years, *SD* standard deviation^a^Population refers to the entire hypothetical cohort of males or females of northern European ancestry Fig. 3Cost-effectiveness scatterplot for the status quo strategy for males (**a**) and females (**b**). *\$A* Australian dollars, *QALYs* quality-adjusted life-years

Time in States {#Sec16}
--------------

The model projected the time spent in each disease state (Table [4](#Tab4){ref-type="table"}). The low rates of uptake of screening and adherence to treatment were the drivers of transition to Categories 3 and 4, the states in which co-morbidities related to iron overload occur. Males spent a mean of 23 years in Category 3 and 3 years in Category 4, whilst females, with lower clinical penetrance, spent a projected mean of 6 years in Category 3 and less than 1 year in Category 4.

The model predicted the probabilities of both the male and female cohorts being in each of the five Markov states for each stage of the model, until all hypothetical participants were in the absorbing 'Death' state (Fig. [4](#Fig4){ref-type="fig"}a, b). For both sexes, the probability of being in Category 1 increased between the first two stages, and, conversely, the probability of being in Category 2 decreased. This result is a function of screening, in that 90.5% of Category 2 patients access treatment subsequent to screening. Therefore, most Category 2 participants transition to Category 1, the impacts of haemochromatosis being potentially reversible until Category 4. This effect is less dramatic for females as fewer females than males are in Category 2 at the time of screening (80 and 95%, respectively).Fig. 4State probabilities for (**a**) male C282Y homozygotes and (**b**) female C282Y homozygotes

For both sexes, the probability of being in Category 1 decreased over time, reflecting reduced adherence to treatment: from 90.5% in the first year to 29.3% in the tenth year and thereafter \[[@CR30]\]. In turn, the probability of being in Categories 2, 3 or 4 increased. Participants in Category 4 had a higher probability of moving into the 'Death' state than other participants. In addition, the probability of transitioning into the 'Death' state increased with the advancing age of the cohort, in line with population data \[[@CR24]\].

Sensitivity Analysis {#Sec17}
--------------------

One-way sensitivity analyses were carried out by varying the value by ±20% for all key parameters, with the exception of uptake of screening (±50%) and discounting (varied between 0 and 7%) ("Appendix [2](#Sec21){ref-type="sec"}"). Tornado diagrams were constructed to identify parameters with the greatest effect on costs and effectiveness. The five parameters with the greatest impact (discount rate, prevalence, probability of starting in Category 1, transition from Category 1 to 2 and costs associated with Categories 2 and 3) are included in "Appendix [2](#Sec21){ref-type="sec"}".

For males, varying the discount rate had the most notable effect on both costs and effectiveness. With no discounting, mean costs increased from the base-case estimate of \$A145 to \$A497 and effectiveness increased from 15.7 to 42.2 QALYs. When the discount rate was set at 7%, mean costs decreased to \$A101 and effectiveness reduced to 11.9 QALYs. Varying the prevalence also had an impact on costs: increasing the estimate by 20% increased mean costs to \$A185, and decreasing the estimated by 20% reduced costs to \$A126. Varying uptake of screening (±50%) marginally impacted costs and effectiveness. Decreasing uptake reduced costs to \$A143, and increasing uptake increased costs to \$A146. No notable impact on effectiveness was observed (\<0.001 QALY). Varying the mortality multiplier had negligible effects on cost and effectiveness for males (\<\$A1 and \< 0.001 QALY, respectively). For LE, varying the multiplier for mortality by ±20% (1.96--2.94) resulted in small changes. For males aged 30 years, decreasing the multiplier increased LE to 50.2 years from a base-case LE estimate of 40.1 years, and, conversely, increasing the multiplier decreased LE to 49.7 years. One-way sensitivity analysis on other variables showed small impacts on costs and effectiveness ("Appendix [2](#Sec21){ref-type="sec"}").

For females, the parameter with the most effect on costs and effectiveness was the discount rate. Decreasing this to zero resulted in costs increasing to \$A264 from the base-case estimate of \$A91, and increasing this rate to 7% decreased costs to \$A64. Similarly, effectiveness increased from the base-case estimate of 14.4 to 33.1 QALYs gained with no discounting and decreased to 11.3 QALYs gained when the discount rate was set at 7%. Increasing the prevalence estimate increased costs to \$A114; when this was decreased, costs reduced to \$A79. Decreasing the uptake estimate by 50% reduced costs to \$A89, and increasing this estimate increased costs to \$A93. No notable change in effectiveness was observed (\< 0.001 QALY). Similar to males, varying the mortality multiplier had negligible effects on costs and effectiveness (\<\$A1 and \<0.001 QALY gained, respectively). The LE of females aged 45 years increased by \<0.01 years when the multiplier was decreased by 20% (40.2 years), and, conversely, LE decreased to 40.1 years when the multiplier was increased. All other sensitivity analyses revealed minor changes from the base-case estimate ("Appendix [2](#Sec21){ref-type="sec"}").

Discussion {#Sec18}
==========

This is the first economic model to be published using utility and cost data from a haemochromatosis cohort to populate a Markov model with probabilistic decision analysis---the approach best suited to this chronic, progressive disease. Just one other model has evaluated the cost effectiveness of population screening for haemochromatosis, using a Markov model with probabilistic decision analysis \[[@CR25]\]. Our model has built on this previously published model by incorporating multiple disease states as recommended by the EASL, along with disease-specific cost and utility data derived from people living with haemochromatosis. Previous models used estimates of costs and utilities based on expert opinion \[[@CR5], [@CR26], [@CR48], [@CR49]\].

The number of health technology assessments being conducted has increased over the past two decades and, with an increasing focus on value in healthcare, this is likely to continue. Whilst clinical studies are ideally placed to assess the short- to medium-term costs and effectiveness of interventions, long-term costs and effectiveness are most feasibly and efficiently assessed through modelling. Important considerations for modelling studies include use of the highest quality clinical and epidemiological data available, transparency, and acceptability to patient groups, expert clinicians, decision makers and healthcare payers. The model for haemochromatosis that we have constructed has aimed to address all of these issues.

The model was assessed for internal validity using linear regression. The *R* ^2^ values of the slopes indicated the modelled projections closely correlated with the inputted and external data. All key input parameters, results of one-way sensitivity analyses and the structure of the model have been provided to enhance transparency. A limitation of this study was that external validation of the model was not conducted. To date, limited data on the long-term clinical and health economic outcomes of haemochromatosis have been published. As a result, where these data were available, they were used in the construction of the model, thereby rendering external validation not possible.

The base-case analyses estimated the mean direct medical costs associated with screening and consequential treatment for those identified was \$A145 for males and \$A91 for females. The higher costs incurred by males than females are expected given the higher rate of clinical penetrance for males. One-way sensitivity analysis identified no parameters which altered this. Increasing the penetrance for females by increasing the probability of commencing in Category 2 (rather than Category 1) had a negligible effect on costs and effectiveness in comparison to the base-case results. Another factor contributing to the lower costs for females is the low sensitivity of TfS as a screening test for females. This results in missed diagnoses and lower total screening costs (two consecutive elevated TfS tests followed by confirmatory genotype) as fewer females than males will go on to have the second TfS test and genotype. In turn, potential venesection treatment costs are not accrued. Whilst in our model female C282Y homozygotes who are not diagnosed, and therefore not receiving treatment, still accrue costs (with the exception of Category 1), these costs are smaller as venesection costs are excluded. Further, treatment costs accrue in the future, and are thus subject to discounting. Overall, the trade-off for this lower cost screening strategy is the reduced identification of female homozygotes. The trade-off between any cost savings versus the greater burden of disease generated is an issue that requires careful consideration.

Our model, consistent with other published studies, reported relatively high levels of uncertainty as evidenced by large standard deviations and 95% CIs reported in the base-case analyses \[[@CR4], [@CR25], [@CR41], [@CR50], [@CR51]\]. However, these uncertainties were addressed in our one-way sensitivity analyses and, with the exception of discounting, were found to have little impact on the base-case results. Our primary avenue to minimise uncertainty was by utilising patient-derived information on costs and utilities associated with EASL categorisations.

One-way sensitivity analyses were conducted by varying the base parameter values by ±20%, with the exception of uptake of screening (±50%). For these parameters, the 95% CIs were within the ±20% ranges adopted. Whilst conducting one-way sensitivity analyses by varying the base parameter values by ±20% is an approach recommended by ISPOR \[[@CR44]\], using the 95% CIs for each parameter represents an alternative, useful approach.

Projected LE for C282Y homozygotes was marginally lower than for the general population. The mortality multiplier applied to Category 4 of 2.45 \[[@CR39]\] was in-line with other recent epidemiological work on mortality associated with haemochromatosis \[[@CR52]\]. Whilst higher mortality rates were adopted for Category 4, the low penetrance rate for this category resulted in marginal impacts on overall mortality in both the base-case and sensitivity analyses.

Our model has been developed to allow for comparisons between the status quo approach of screening for haemochromatosis and alternatives, such as population-level genetic or neonatal screening \[[@CR53]\]. Our model is well-placed to assist decision makers in Australia to assess different screening strategies for haemochromatosis. Further, it is flexible enough that alternative parameters may be used to allow for cost-effectiveness analyses in different jurisdictions.

Conclusion {#Sec19}
==========

A transparent and validated health economics model of screening for C282Y homozygote haemochromatosis based on Australian economic, epidemiological and clinical data has been developed. The model will be useful to decision makers to identify cost-effective screening and treatment strategies for C282Y homozygote haemochromatosis.

Appendix 1 {#Sec20}
==========

See Fig. [5](#Fig5){ref-type="fig"}.Fig. 5Flowchart of screening processes. *GP* general practitioner, *HMZ* homozygote

Appendix 2 {#Sec21}
==========

See Table [5](#Tab5){ref-type="table"}.Table 5One-way sensitivity analyses: males and femalesParametersGovernment perspectiveCosts^a^Effectiveness^b^Males Discount rate: 0%49742.246 Discount rate: 7%10111.903 Prevalence: −20%12615.453 Prevalence: +20%18515.451 Probability of starting in category 1: −20%15815.451 Probability of starting in category 1: +20%12715.454 Transition from category 1 to 2^c^: --20%13315.453 Transition from category 1 to 2^c^: +20%15115.453 Costs: category 3(no treatment): 20%^d^12915.453 Costs: category 3(no treatment): +20%^d^15615.453Females Discount rate: 0%26433.124 Discount rate: 7%6411.286 Prevalence: --20%7914.281 Prevalence: +20%11414.277 Costs: category 2(no treatment): −20%7614.280 Costs: category 2(no treatment): +20%10114.280 Probability of starting in category 1: −20%10714.280 Probability of starting in category 1: +20%8414.280 Transition from category 1 to 2^c^: −20%7914.280 Transition from category 1 to 2^c^: +20%9714.280^a^Costs are lifetime costs reported in 2015 Australian dollars^b^Effectiveness is presented in quality-adjusted life-years^c^Amongst patients not receiving treatment^d^At time of diagnosis, in the base-case this is assumed to be 0
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